CJC-1295 vs MK-677 (Ibutamoren)
A side-by-side research comparison of CJC-1295 and MK-677 (Ibutamoren) across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | CJC-1295 | MK-677 (Ibutamoren) |
|---|---|---|
| Full name | CJC-1295 (Modified GRF 1-29) | Ibutamoren Mesylate (MK-677) |
| Category | Growth Hormone | Growth Hormone |
| Status | Research compound | Investigational |
| Mechanism | Binds GHRH receptors on anterior pituitary somatotrophs, stimulating cAMP-dependent GH synthesis and pulsatile release. | Acts as ghrelin mimetic at GHS-R1a receptors in hypothalamus and pituitary. Excellent oral bioavailability and 24-hour duration. |
| Molecular weight | 3,368 Da (without DAC) | 528.7 Da |
| Half-life | 30 minutes (no DAC) / 8 days (with DAC) | 24 hours |
| Bioavailability | High (SubQ) | High (oral) |
| Typical dose | 100-300 mcg | 10-25 mg |
| Frequency | 1-3x daily (no-DAC) | Once daily |
| Route | Subcutaneous injection | Oral (capsule/liquid) |
CJC-1295 reported benefits
- Increased GH production
- Improved body composition
- Enhanced recovery
- Better sleep quality
- Anti-aging effects
- Fat loss
MK-677 (Ibutamoren) reported benefits
- Oral administration
- Sustained 24h GH elevation
- Increased IGF-1
- Improved sleep depth
- Enhanced recovery
- Bone density support
Related comparisons
Research and educational reference only. Not medical advice.